News

ImCheck Therapeutics receives EMA Orphan Drug Designation for ICT01 for treatment for acute myeloid leukemia: Marseille, France Thursday, July 24, 2025, 15:00 Hrs [IST] ImCheck Th ...
French biotech ImCheck Therapeutics has announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A ...
ImCheck Therapeutics raises €20 Million and appoints its CEO Emerging leader in immuno-oncology accelerates its development programs and prepares for entry into the clinic Marseille, France, May ...
ImCheck Therapeutics just raised $103 million to treat multiple forms of cancer. The company is working on one of the fastest-growing ideas in cancer research: gamma-delta T cells.
ImCheck Therapeutics’ contribution is a type of drug that could bring advantages over the first generation of cancer immunotherapies. Now the biotech has €96M that will help continue clinical ...
ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023Interim data from Phase I dose escalation portion of ...
Marseille, France, May 22, 2025, 5:00 pm ET/11:00 pm CET – ImCheck Therapeutics today announced the publication of its abstract for an upcoming oral presentation at the 2025 American Society of ...
With all that on the to-do list, ImCheck Therapeutics has refueled with a 96 million euro ($101 million) funding round that featured existing investors Pfizer, Gimv and more.
ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...